The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis

Author： Swart Joost Frans   Barug Daantje   Möhlmann Michelle   Wulffraat Nico M  

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.10, Iss.12, 2010-12, pp. : 1743-1752

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis

By Fleischmann Roy   Stern Richard   Iqbal Imran  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 8, 2004-08 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Update on biologicals for treatment of juvenile idiopathic arthritis

By Horneff Gerd  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 3, 2013-03 ,pp. : 361-376

Informa Healthcare

Access to resources Recommend Favorite

Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis

By Berard Roberta A   Laxer Ronald M  

Expert Opinion on Biological Therapy, Vol. 13, Iss. 11, 2013-11 ,pp. : 1623-1630

Informa Healthcare

Access to resources Recommend Favorite

The efficacy and safety of golimumab in the treatment of arthritis

By Fleischmann Roy  

Expert Opinion on Biological Therapy, Vol. 10, Iss. 7, 2010-07 ,pp. : 1131-1143

Informa Healthcare

Access to resources Recommend Favorite

Interleukin-1 receptor antagonist as therapy for inflammatory disorders

By Freeman B.D.   Buchman T.G.  

Expert Opinion on Biological Therapy, Vol. 1, Iss. 2, 2001-03 ,pp. : 301-308

Informa Healthcare

Access to resources Recommend Favorite